Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Brian D. Kent, Grainne d'Ancona, Mariana Fernandes, Linda Green, Cris Roxas, Louise Thomson, Alexandra M. Nanzer, Joanne Kavanagh, Sangita Agarwal, David J. Jackson. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019

Member's Comments

No comment yet.

Related content which might interest you: Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020 Year: 2020 Mepolizumab as a steroid-sparing agent for eosinophilic granulomatosis with poliangiitis: a case series Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Biologics for eosinophilic granulomatosis with polyangiitis Source: Short video statement 2020 Year: 2020 Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2019; 86: 188-209 Year: 2019 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2022; 95: 177-192 Year: 2022 Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases Year: 2020 ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Granulomatosis with polyangiitis (Wegener&s) Source: Eur Respir Mon 2011; 54: 1-14 Year: 2011 New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab Source: Eur Respir J 2006; 27: 644-646 Year: 2006 Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon Year: 2018 Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA) Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Aerosolized tobramycin in patients with Wegener's granulomatosis Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Pulmonary hypertension as the first manifestation in a patient with granulomatosis with polyangiitis Source: International Congress 2019 – Pulmonary vascular diseases? Year: 2019 Microscopic polyangiitis and granulomatosis with polyangiitis Source: Eur Respir Monogr 2019; 86: 153-172 Year: 2019 Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) Source: Eur Respir J 2016; 48: 1429-1441 Year: 2016 Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Clinical management of orphan lung diseases Year: 2013 The role of intratracheal dilation – Injection technique in treatment of granulomatosis with polyangiitis (GPA) patients with subglottic stenosis Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016